LifeCycle Pharma A/S Announces Successful Completion of Pilot Studies on LCP-Feno and is Currently Preparing for Pivotal Studies.

Company Announcement no. 24/2008

To: OMX Nordic Exchange Copenhagen		       Hørsholm, Denmark, May 28, 2008.


LifeCycle Pharma A/S Announces Successful Completion of Pilot Studies on
LCP-Feno 
and is Currently Preparing for Pivotal Studies 
LifeCycle Pharma Discontinues Service Agreements with Partners
LifeCycle Pharma A/S (OMX:LCP) today announced the successful completion of
pilot studies for LCP-Feno, a product for the treatment of dyslipidemia which
is being developed in collaboration with Sandoz Inc. LCP-Feno is designed to be
an AB-rated, substitutable version of Tricor® 145 mg, currently marketed in the
US by Abbott under the name Tricor® and in Europe by Solvay S.A. under the name
Lipanthyl ®. In collaboration with Sandoz, LifeCycle Pharma is currently
preparing for the initiation of pivotal studies to complete all the necessary
requirements for a US ANDA filing. 

“We are extremely pleased to have shown bioequivalence of LCP-Feno and Tricor®
in this pilot study,” said Dr. Michael Beckert, LifeCycle Pharma's Chief
Medical Officer and Executive Vice President. “This is another important
milestone for the company, and a clear validation of the breadth of application
as well as versatility of the MeltDose® technology. The next step will be to
prepare for pivotal pharmacokinetic studies to confirm these results.” 

About the collaboration with Sandoz
Sandoz and LifeCycle Pharma entered into an exclusive development and
commercialization agreement for LCP-Feno for the US market in September 2006.
The parties are jointly responsible for the future development, and Sandoz will
be solely responsible for later commercialization of LCP-Feno in the US.
LifeCycle Pharma will receive milestone payments as well as a significant
double-digit royalty rate on future sales. In 2006, the worldwide sales of all
fenofibrate products were approximately USD 1.7 billion (IMS Health; All rights
reserved). 

Pipeline prioritization and discontinuation of two smaller service agreements
LifeCycle Pharma has a broad pipeline, primarily focused on select
transplantation and cardiovascular products, two of which, LCP-Tacro and
LCP-Atorfen, are expected soon to enter into Phase III.  LifeCycle Pharma has
also historically had a number of service (re-)formulation agreements with
other companies. In order to optimize the use of scarce resources and focus the
clinical development organization, a first step in prioritizing the pipeline
has been to terminate a few service agreements outside the core therapeutic
areas of interest for LifeCycle Pharma. 

Therefore, LifeCycle Pharma today announced the discontinuation of both the
LCP-Lerc service agreement with Recordati and the feasibility study agreement
with Sciele Pharma. In agreement with LifeCycle Pharma, Recordati has decided
to discontinue the LCP-Lerc service agreement which encompasses the development
of a novel version of Recordati's lercanidipine (Zanidip®) for the treatment of
hypertension. In addition, LifeCycle Pharma and Sciele Pharma mutually agreed
to discontinue the feasibility study agreement pertaining to a product in
preclinical development. 

“We can now focus resources on our most promising pipeline projects. I am
pleased to announce that we today have taken a first important step in this
direction,” says Hans Christian Teisen, LifeCycle Pharma's CFO and Executive
Vice President. “We are also in the process of determining the organizational
best route forward to optimize the MeltDose® technology in terms of service
arrangements without distracting from our core focus which is transplantation
and the immunosuppression market,” he explained. 

Contact:
LifeCycle Pharma A/S
Hans Christian Teisen
Executive Vice President and CFO
+45 2030 6985
HCT@lcpharma.com

About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceutical company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop
drugs with enhanced absorption and thereby increased bioavailability. LCP has a
cholesterol lowering product, FenoglideTM, currently on the US market and a
diversified near- and medium-term pipeline, including four product candidates
in clinical trials and two in preclinical stages of development. LCP is listed
on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For
further information, please visit www.lcpharma.com.